4th EUROPEAN BIOTECH & MEDTECH INVESTOR DAY

by France Biotech
MISSION

To improve acceptance and compliance of allergy immunotherapy by developing short course treatments based on innovative allergenic peptides.

TECHNOLOGY

ASIT+™ technology is based on carefully size selected and qualified natural peptides extracted from highly purified original allergen.

COMPETITION

Aimmune /ALK-Abello / Stallergenes Greer

ALLIANCES/PARTNERSHIPS

Imperial College London, Kings College London, Walloon Region

UPCOMING CATALYSTS

Preparation of a 2nd Phase III in Europe in grass pollen allergy with site selection in Q4 2018 and first-patient first-visit in Q1 2019.

Selection of a product candidate with the best immunogenicity profile for further clinical development in house dust mite allergy – Q2/Q3 2018.

Selection of a product candidate with the best immunogenicity profile for further clinical development in food allergy, stating with peanut – Q2/Q3 2018.

MARKET FIGURES (listed companies)

Revenues 2017: n.s.

Date of IPO: 11 May 2016

Ticker: ASIT

Exchange: Euronext Brussels & Paris

Currency: EUR

Market cap: €60.8m (at April 11, 2018)

Price: €3.7 (at April 11, 2018)

52-weeks-high: €7.2

52-weeks-low: €3.2

Average daily volume: 35,188 (last 12 months)

KEY FIGURES

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>Growth (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>n.s.</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>EBIT</td>
<td>-12.3</td>
<td>-12.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Net Income</td>
<td>-12.3</td>
<td>-12.0</td>
<td>n.s.</td>
</tr>
<tr>
<td>Cash Position</td>
<td>13.4</td>
<td>2.1</td>
<td>n.s.</td>
</tr>
</tbody>
</table>
COMPANY SUMMARY
BIO Boston 1x1 meeting

ASIT BIOTECH
NAME OF THE CEO
Thierry LEGON

ASIT biotech's immunotherapy solutions are being developed for patients with allergic rhinitis, especially allergy on grass pollen and house-dust mites (up to 116 million people in the EU & US) and for patients suffering from food allergies (peanut, caw milk, ...).

TARGETED MARKET

SHAREHOLDERS (percentage)

PUBLIC (Regional institutions) 27%
Private (1) 6%
Private (2) 10%
Management 4%

ADRESS
5 avenue Ariane,
1200 Woluwé-Saint-Lambert,
Belgique

EMAIL
philippe.ghem@biotech.be
www.asitbiotech.com

MANAGEMENT TEAM
CEO: M. Thierry Legon
CFO: M. Everard van der Straten
Chief Scientific Officer (CSO): Sabine Pirotton
Chief Medical Officer (CMO): Marie-Eléen Pinelli
Chief Commercial Officer (CCO): Philippe Ghem

LISTED COMPANY

CREATION DATE
1997

ANALYST COVERAGE

<table>
<thead>
<tr>
<th>Broker</th>
<th>Date</th>
<th>Reco. (buy/neutral/hold)</th>
<th>Target Price</th>
<th>Potential (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilbert Dupont</td>
<td>02/05/2018</td>
<td>Reduce</td>
<td>€4.5</td>
<td>22%</td>
</tr>
<tr>
<td>KBC Securities</td>
<td>02/05/2018</td>
<td>Buy</td>
<td>€5.5</td>
<td>49%</td>
</tr>
<tr>
<td>Average:</td>
<td></td>
<td></td>
<td>€5.0</td>
<td>35%</td>
</tr>
</tbody>
</table>

PIERCED PHASE III
Preclinical development program

PREVIOUS PHASES

Grass pollen

House dust mite

Food

PREVIOUS PHASES

Q1 2017 - Positive phase III

Q2 2017 - Positive Phase II

Future Phases

food-ASIT™

egg-ASIT™